Evidence map›Paper›PMID 34339028›Full record

ArticleAdvances in experimental medicine and biology2021

Epithelial Ovarian Cancer and Cancer Stem Cells.

Amr A Soliman, Alaa A Elzarkaa, Eduard Malik

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Wnt antagonist as therapeutic targets in ovarian cancer.The international journal of biochemistry & cell biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amr A SolimanUniversitätsklinik für Gynäkologie und Geburtshilfe, Klinikum Oldenburg AöR, Carl von Ossietzky Universität, Oldenburg, Oldenburg, Germany. amr.soliman@uni-oldenburg.de.
Alaa A ElzarkaaEl-Shatby University Maternity Hospital, University of Alexandria, Alexandria, Egypt.
Eduard MalikUniversitätsklinik für Gynäkologie und Geburtshilfe, Klinikum Oldenburg AöR, Carl von Ossietzky Universität, Oldenburg, Oldenburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer is a lethal gynecological cancer. It is related to high mortality because the majority of the patients present in advanced stage and because of the high recurrence rates of the disease. Recurrent ovarian cancer is classified according to the time interval between the last platinum-based chemotherapy and the occurrence of recurrence, to platinum-sensitive and platinum-resistant. Many theories tried to explain development of resistance to platinum-based therapy. "Cancer stem cells" is one of these theories and is being currently under investigation by many groups. This chapter will demonstrate the suggested contribution of cancer stem cells to the development of recurrent ovarian cancer.

Indexed as

Neoplasms, Glandular and EpithelialOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialDrug Resistance, NeoplasmFemaleHumansNeoplasm Recurrence, LocalNeoplastic Stem CellsPlatinumPlatinumCancer stem cellsChemotherapy resistanceOvarian cancerTreatment

Identifiers

PMID34339028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.